anti-CD28/anti-CEACAM5 bispecific antibody (Xencor)

N/A

Report date: 2026/03/19 16:57:17

Base Information

Drug Nameanti-CD28/anti-CEACAM5 bispecific antibody (Xencor)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonistsT-cell-specific surface glycoprotein CD28 inhibitors
TargetsT-cell-specific surface glycoprotein CD28Carcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesXencor Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A